Taiwan · Delayed Price · Currency is TWD Chimerix Statistics
Total Valuation
Syngen Biotech has a market cap or net worth of TWD 3.27 billion. The enterprise value is 3.31 billion.
| Market Cap | 3.27B |
| Enterprise Value | 3.31B |
Important Dates
The next estimated earnings date is Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | Jun 26, 2025 |
Share Statistics
Syngen Biotech has 27.10 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 27.10M |
| Shares Outstanding | 27.10M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 8.15% |
| Owned by Institutions (%) | 3.27% |
| Float | 10.54M |
Valuation Ratios
The trailing PE ratio is 11.71.
| PE Ratio | 11.71 |
| Forward PE | n/a |
| PS Ratio | 1.54 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.48 |
| P/FCF Ratio | 10.02 |
| P/OCF Ratio | 8.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.95, with an EV/FCF ratio of 10.14.
| EV / Earnings | 11.83 |
| EV / Sales | 1.56 |
| EV / EBITDA | 6.95 |
| EV / EBIT | 9.32 |
| EV / FCF | 10.14 |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.12.
| Current Ratio | 1.75 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.55 |
| Debt / FCF | 0.80 |
| Interest Coverage | 47.55 |
Financial Efficiency
Return on equity (ROE) is 12.82% and return on invested capital (ROIC) is 8.70%.
| Return on Equity (ROE) | 12.82% |
| Return on Assets (ROA) | 7.06% |
| Return on Invested Capital (ROIC) | 8.70% |
| Return on Capital Employed (ROCE) | 14.56% |
| Revenue Per Employee | 8.60M |
| Profits Per Employee | 1.13M |
| Employee Count | 247 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 3.82 |
Taxes
In the past 12 months, Syngen Biotech has paid 68.84 million in taxes.
| Income Tax | 68.84M |
| Effective Tax Rate | 19.77% |
Stock Price Statistics
The stock price has decreased by -24.21% in the last 52 weeks. The beta is 0.12, so Syngen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | -24.21% |
| 50-Day Moving Average | 126.55 |
| 200-Day Moving Average | 128.04 |
| Relative Strength Index (RSI) | 53.40 |
| Average Volume (20 Days) | 81,697 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Syngen Biotech had revenue of TWD 2.12 billion and earned 279.44 million in profits. Earnings per share was 10.29.
| Revenue | 2.12B |
| Gross Profit | 770.35M |
| Operating Income | 355.21M |
| Pretax Income | 348.28M |
| Net Income | 279.44M |
| EBITDA | 460.51M |
| EBIT | 355.21M |
| Earnings Per Share (EPS) | 10.29 |
Balance Sheet
The company has 222.83 million in cash and 262.25 million in debt, giving a net cash position of -39.42 million or -1.45 per share.
| Cash & Cash Equivalents | 222.83M |
| Total Debt | 262.25M |
| Net Cash | -39.42M |
| Net Cash Per Share | -1.45 |
| Equity (Book Value) | 2.25B |
| Book Value Per Share | 82.96 |
| Working Capital | 514.37M |
Cash Flow
In the last 12 months, operating cash flow was 377.47 million and capital expenditures -51.41 million, giving a free cash flow of 326.06 million.
| Operating Cash Flow | 377.47M |
| Capital Expenditures | -51.41M |
| Free Cash Flow | 326.06M |
| FCF Per Share | 12.03 |
Margins
Gross margin is 36.27%, with operating and profit margins of 16.72% and 13.16%.
| Gross Margin | 36.27% |
| Operating Margin | 16.72% |
| Pretax Margin | 16.40% |
| Profit Margin | 13.16% |
| EBITDA Margin | 21.68% |
| EBIT Margin | 16.72% |
| FCF Margin | 15.35% |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 4.27%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 4.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 48.49% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 4.19% |
| Earnings Yield | 8.56% |
| FCF Yield | 9.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.
| Last Split Date | Jul 9, 2018 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Syngen Biotech has an Altman Z-Score of 4.33 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.33 |
| Piotroski F-Score | 8 |